The clinical-grade HLA homozygous iPSC stock manufactured by CiRA_F, which is believed to prevent or minimize immune rejection in many Japanese patients, was provided to iPS Bio, a start-up biotech company in Korea. iPS Bio plans to use CiRA_F's iPSC stock to conduct clinical trials for treating Huntington's disease, stroke, Alzheimer's disease, as well as immune-oncology diseases, in the next few years. The HLA types in Japanese and Korean populations are highly similar, so it is expected that CiRA_F's iPSC stock will reduce the risk of immune rejection when transplanted into HLA-matched patients in Korea as well as in Japan. The clinical-grade HLA homozygous iPSC stock manufactured by CiRA_F, which is believed to prevent or minimize immune rejection in many Japanese patients, was provided to iPS Bio, a start-up biotech company in Korea. iPS Bio plans to use CiRA_F's iPSC stock to conduct clinical trials for treating Huntington's disease, stroke, Alzheimer's disease, as well as immune-oncology diseases, in the next few years. The HLA types in Japanese and Korean populations are highly similar, so it is expected that CiRA_F's iPSC stock will reduce the risk of immune rejection when transplanted into HLA-matched patients in Korea as well as in Japan.